External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ESMO Breast Cancer 2026
Roche and Genentech at

ESMO Breast Cancer 2026

May 06 - May 08
Berlin, Germany / Virtual (Hybrid)
esmo.org
We will be contributing to topics related to
Oncology
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
03:45 PM
Duration 60mins Berlin, Germany
A New Era in Adjuvant Care for HR+ HER2– Breast Cancer
Fatima Cardoso, Sherene Loi, Peter Schmid
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Berlin, Germany
Watch: A New Era in Adjuvant Care for HR+ HER2– Breast Cancer
Fatima Cardoso, Sherene Loi, Peter Schmid
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:15 AM
Duration 60mins Berlin, Germany
Safety and preliminary efficacy of giredestrant (GIRE) + the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) + palbociclib (PALBO) in MORPHEUS-Breast Cancer (BC): A Phase Ib/II trial in patients (pts) with oestrogen receptor-positive, HER2-positive (ER+, HER2+) metastatic (m)BC
Ana Mafalda Antunes Melo Oliveira, Annie Collier, Gregory Vidal, Jing Zhu, Keun Seok Lee, Maria Gion Cortes, Melinda Telli, Miranda Craft, Richard Schwab, Stephen Luen, Uwe Bader, Yeon Hee Park
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:15 PM
Duration 10mins Berlin Hall
Safety and patient (pt)-reported outcomes (PROs) from evERA Breast Cancer (BC): A Phase III trial of giredestrant (GIRE) + everolimus (E) in pts with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i)
Miguel Martín, Erica L. Mayer, Luca Moscetti, Sara M. Tolaney, Gregory A. Vidal, Komal L. Jhaveri, Adam Brufsky, William J. Gradishar, Andreas Schneeweiss, Norikazu Masuda, Amy Tiersten, Begoña Bermejo De Las Heras, Valeria Caceres, Gun Min Kim, Mona D. Shah, Sheetal Patel, Raj Brahmbhatt, Alejandra Benitez, Lisa H. Lam, Hope S. Rugo
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:35 AM
Duration 5mins Berlin Hall
Efficacy of inavolisib▼ (INAVO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) with and without hyperglycaemia (HG) in the Phase III INAVO120 trial
Cristina Saura, Dejan Juric, Fatima Cardoso, Karen Cheng, Kevin Kalinsky, Komal Jhaveri, Luis De la Cruz Merino, Nicholas Turner, Oleksandr Dudnichenko, Peter Schmid, Seock-Ah Im, Sherene Loi, Sibylle Loibl, Thomas Stout, Yanling Jin
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.